Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine Patch in AD with Small Vessel Cerebrovascular Disease
NCT02444637Phase 4Completed
- Sponsor
- National Neuroscience Institute
- Start
- Apr 2015
- Primary completion
- Mar 2019
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of rivastigmine in Alzheimer's disease (AD), sponsored by National Neuroscience Institute. Started Apr 2015; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02444637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02444637.